Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive status confers therapeutic sensitivity to Exemestane in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized exemestane for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive invasive early breast cancer (EBC) who have received 2 to 3 years of initial tamoxifen therapy.
This statement is based on a regulatory approval from the Health Products Regulatory Authority:
Aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer (EBC), following 2 – 3 years of initial adjuvant tamoxifen therapy.